Send to

Choose Destination
J Cancer Res Ther. 2018;14(7):1578-1582. doi: 10.4103/jcrt.JCRT_210_18.

Diagnosis and treatment of hemangiopericytoma in the central nervous system.

Author information

Department of Radiation Oncology, Chinese PLA General Hospital, Beijing, China.
Department of Radiation Oncology, First Affiliated Hospital of PLA General Hospital, Beijing, China.



This study aimed to explore the clinical characteristics and treatment of the hemangiopericytoma (HPC) in the central nervous system.

Materials and Methods:

Clinical data from 14 patients with HPC in the central nervous system who were followed up for 12-107 months were retrospectively analyzed, and relevant literature was reviewed.


All 14 patients underwent surgery and postoperative pathologic diagnosis, including 8 cases of total excision, 3 cases of subtotal excision, and 3 cases of partial excision. There were 7 recurrent cases (50%, 4 cases of total excision, 1 case of subtotal excision, and 2 cases of partial excision, none of them received postoperative radiotherapy) with a median relapse time of 39 months, where the median relapse time after total excision was 41.5 months, and after nontotal excision was 17 months. In addition, patients could survive for a long time after reoperation following relapse and after receiving postoperative radiotherapy.


The diagnosis of HPC depends on the pathology. Currently, the surgery and postoperative radiotherapy provide a good treatment results, while the wholeness of surgical resection is of particular importance.


Central nervous system; clinical features; hemangiopericytoma; radiotherapy

Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center